. This is an index qualitatively descriptive study; no statistical analysis was pursued.
Method of SVF isolation
Fresh human waste lipoaspirate from informed and consented three healthy females were used for this University of Florida Jacksonville Institutional Review Board approved study (IRB# 201601520). Each of the three lipoaspirate samples was used to prospectively establish a cell line, from initial ASC expansion to differentiation and analysis. The lipoaspirate had been harvested using standard operative tumescent techniques using syringe liposuction. The tumescent solution included normal saline, lidocaine, and epinephrine. Shortly af-ter harvest, the fresh lipoaspirate was then processed using the "Reviticell Kit" (Reviticell, Inc., Jacksonville, FL) with its inherent 10-step process. In brief, shortly after the lipoaspirate was obtained, 70mls of unconcentrated lipoaspirate was measured out and subsequently underwent intersyringe transfer (between two 60 ml syringes provided as part of the Reviticell Kit) for five transfers. Then, 17.5 ml of lipoaspirate was placed into each of four 35 
Method of ASC expansion
The SVF was added to 6 MLS of animal component free 
Tri-lineage differentiation

Results
After expansion for 10 days in vitro(see figure 2 ), ASCs By an average of the three cell lines, the osteogenic progenitor population produced comparatively the greatest quantity of VEGF-A 165 , maximally on day 14 at 1,684.73 pg/ml. The chondrogenic lineage consistently produced VEGF-A 165 , albeit in considerably fewer quantities. The greatest increase in VEGF-A 165 production was between days 7 and 14: 186% increase of VEGF-A 165 within the osteogenic progenitor lineage. (see Figure   7 ). As this study quantitated secreted VEGF-A 165 longitudinally among three separate cell lines as harvested from three different patients, each cell line produced comparatively different quantities of VEGF-A 165 (see Figure 8 ). However, secreted quantities of VEGF-A 165 trended similarly within each cell line.
Calculating VEGF-A 165 per million cells was based on
an average of 650,000 cells per 9cm 2 well. As the media volume within each well at each point of supernatant sampling was 2 ml, peak VEGF-A 165 levels were 5.18 ng/ million cells for osteogenic APCs (sampled at day 14), 4.69 ng/ million cells for adipogenic APCs (sampled at day 14), 4.23ng/ million cells for undifferentiated APCs (sampled at day 21), and 1.26 ng/ millions cells for chondrogenic APCs (sampled at day 14). See Figure 9 .
Current Good Manufacturing Grade rVEGF-A 165 (Cat# 293GMP, R&D Systems, Minneapolis, MN) stimulates proliferation of human umbilical vein endothelial cells (HUVECs). The ED 50 (median effective dose) for this standard effect is 1 ng/mL with a specific activity of approximately 1.7 x 10 3 U/μg. In the current study, 1.685 ng/mL (1,685 pg/mL) was maximally elaborated as sampled, or 3.37 ng total for 650,000 osteogenic cells (2ml/well of 650,000 cells). Osteogenic APCs would achieve ED 50 for HUVEC stimulation of 1ng/ml at 1.93 x 10 5 cells (sampled at day 14), 2.13 x 10 5 cells for adipogenic APCs (sampled at day 14), 2.36 x 10 5 cells for undifferentiated ASCs (sampled at day 21), and 7.92 x 10 5 cells for chondrogenic APCs(sampled at day 14). See Figure 10 . Additionally, based on comparative VEGF-A 165 activity of osteogenic APCS, one would need 9.4% more adipogenic APCs, 18.2% more undifferentiated ASCs, or 75.6% more chondrogenic APCs to generate the same level of enzymatic activity of osteogenic APCs.
Discussion
ARCserve an essential role in cardiac cell and tissue regeneration by offering both structural and hormonal regenerative capabilities. From a structural perspective, ASCs exist in an undifferentiated state, with the ability to self-renew and differentiate along several mesodermal APC lineages [8, 9, [30] [31] [32] [33] [34] [35] .
Additionally, animal studies have shown that ASCs have the potential to differentiate in vivo into endothelial cells and cardiomyocytes [34, 36, 37] . While the maintenance and production of vessels rely on several growth factors and cytokines, VEGF is one of the most critical and well-studied angiogenic growth factors [38] . Hormonally, ASCs have been shown to improve blood flow in a mouse model of hind limb ischemia by secreting angiogenic growth factors, including VEGF [39] .
While it appears counterintuitive to deliver osteogenic
APCs to adult cardiac tissues damaged by ischemia, it is noteworthy to mention that bone morphogenetic proteins play a well-established role in both vascular growth [40] and cardiac development [41] . Heterotopic bone formation is also a consistent finding in valvular heart disease [42] . Up-regulating angiogenesis and down-regulating bone formation in the therapeutic use of osteogenic APCs for cardiovascular disease will be critical. The current study demonstrates that APCs secreted levels of VEGF-A 165 in a lineage-dependent manner and osteogenic APCs This osteogenic progenitor sphere has been stained with Alizarin Red (for calcium) and DAB (for VEGF-A 165 ), 20x mag. The staining is comparatively lighter than with DAB alone and darker than Alizarin Red alone, diagnostic for an osteogenic progenitor sphere producing VEGF-A 165 . [43, 44] but, not osteoblast differentiation [45] . The latter finding suggests that enhanced VEGF-A secretion is not a sufficient determinant of bone formation by osteogenic APCs. In this current study, it may be intuitive to assume that a homogenous population of ASCs treated with an osteogenic differentiation medium may become VEGF-A 165 se- Therapeutic in vivo tissue regeneration will require the classical components that ex vivo tissue engineering requires: matrix scaffolds, cells, and signaling molecules. However, a stark difference between in vivo and ex vivo tissue engineering will be the inherent more complex dynamics between these three entities as appreciated vivo. While the complete characterization of ASCs, much fewer APCs, is currently unknown, designing regenerative therapies that will leverage the original biological characteristics of these therapeutic cells will be mandatory. As can be seen from the three cell lines, each cell line produced differing quantities of VEGF-A 165 though each cell line was cultured in ostensibly same culture conditions. A limitation of this study is the small sample size (three cell lines) and certainly, further studies instituting a greater cell line quantity will be needed to better assess these current findings. Finally, while speculative, including ASCs as cellular constituents to the tissue-building process, may afford unintended benefits; for example, they may differ to fibroblasts to produce matrix proteins (such as collagen), they may differentiate to cells to stabilize the micro-milieu (such as in their anti-inflammatory abilities), and they may differ to cells to produce signaling cytokines (such as VEGF). However, what is not speculative is that we cannot live without them. Matching their original biological characteristics to targeted therapies will be essential in establishing much-needed healthcare solutions. 
Conclusions
